



¹ Science, Evidence and Analytics Directorate, Science Policy and Research Programme, National Institute for Health and Care Excellence, London, UK

² Department of Health Policy, London School of Economics and Political Science, London, UK

³ Centre for Research on Health and Social Care Management, SDA Bocconi, Milan, Italy

⁴ College of Medicine and Health, University of Exeter, Exeter, UK

⁵ Biostatistics Research Group, Department of Health Sciences, University of Leicester, Leicester, UK

Correspondence to: H Naci
H.Naci@lse.ac.uk

Cite this as: *BMJ* 2021;374:n2191
<http://dx.doi.org/10.1136/bmj.n2191>

Published: 16 September 2021

Raising the bar for using surrogate endpoints in drug regulation and health technology assessment

Surrogate endpoints provide no guarantee of clinical benefit, and **Dalia Dawoud and colleagues** argue they should be used only as a last resort in drug trials

Dalia Dawoud,¹ Huseyin Naci,² Oriana Ciani,^{3,4} Sylwia Bujkiewicz⁵

In June 2021, the US Food and Drug Administration granted accelerated approval to aducanumab for treating Alzheimer's disease based on the drug's amyloid reducing effects. This was despite evidence from several earlier studies that shrinkage of β -amyloid protein plaques does not predictably delay cognitive impairment.¹ The controversial decision has drawn attention to the use of surrogate endpoints—laboratory values, radiographic images, or other physical measures that may serve as indicators of clinical outcomes such as symptom control or mortality—in clinical trials of new drugs.² In fact, the approval of aducanumab is only the latest example of growing regulatory reliance on surrogate endpoints, even though their use can cause problems for patients, clinicians, drug regulators, and health technology assessment bodies.

We argue for more selective use of surrogate endpoints when evaluating new drugs, restricting their use to chronic diseases, especially when collecting data on patient relevant clinical outcomes requires trials with unattainably long follow up.

The problem with surrogates

Using surrogate endpoints to measure whether a new drug works can reduce the duration, cost, and complexity of clinical trials before regulatory assessment and facilitate faster patient access to new therapies, especially for chronic diseases.³ For example, in early stage gastric cancer, clinical outcomes such as overall survival—how long patients live after receiving treatment—are of primary interest to patients, but surrogate endpoints such as disease-free survival can potentially provide earlier indications of a drug's effect.⁴ In a recent evaluation, using surrogate endpoints in cancer drug trials reduced clinical development time by about 11 months compared with measuring overall survival.³ However, the use of such endpoints can also have negative implications.

Regulatory reliance on surrogate endpoints makes it challenging for health technology assessment bodies such as the National Institute for Health and Care Excellence (NICE) to make decisions. These bodies typically compare clinical and cost effectiveness of treatments. When new drugs are approved based on surrogate endpoints alone, assessing how well they work in terms of patient relevant clinical outcomes, such as health related quality of life and survival, in the short and long term are fraught with considerable uncertainty.

For patients and clinicians, surrogate endpoints can complicate treatment decisions.⁵ Clinicians and patients may misinterpret drug effects on surrogate endpoints as clinically meaningful improvements.⁶ This matters, because drugs approved on the basis of surrogate endpoints may not ultimately influence patient relevant outcomes. In cancer, for example, most approved drugs with effects on surrogate endpoints such as response rates and progression-free survival (that were imagined to predict patient relevant benefit) do not, in fact, improve quality of life or prolong survival.⁷⁻⁹

There is a long history of drugs that were originally approved on the basis of surrogate endpoints and for which later studies failed to show evidence of clinical benefit.¹⁰ A commonly cited example is bevacizumab for metastatic breast cancer.¹¹ In 2008, the FDA granted the drug accelerated approval based on its early effects on a surrogate endpoint, progression-free survival. This approval was revoked in 2011 when clinical trials failed to show that patients receiving bevacizumab lived longer than those receiving control treatment.

Other examples include olaratumab, which extended progression-free survival but did not prolong survival for patients with soft tissue sarcoma¹²; hydroxyprogesterone caproate, which reduced the risk of recurrent preterm births but did not improve neonatal outcomes¹³; and atezolizumab, which achieved a higher response rate than control treatment but did not extend overall survival in patients with urothelial carcinoma.¹⁴ In some cases, drugs approved on the basis of surrogate endpoints were later found to be harmful. For example, patients with multiple myeloma who received venetoclax had shorter survival than those who received a control treatment, despite evidence that the drug improved progression-free survival.¹⁵

Regulatory enthusiasm

Over the past three decades, the proportion of clinical studies measuring the efficacy of new drugs using surrogate endpoints alone has increased, rising from fewer than 50% in the mid-90s to roughly 60% in 2015-17.¹⁶ In some therapeutic areas such as cancer, surrogate endpoints account for almost 80% of all clinical studies supporting regulatory approvals.¹⁷ This means that in some therapeutic areas, only a minority of new drugs are now approved on the basis of evidence that they improve how patients feel or function, or how long they live.

The recent proliferation of surrogate endpoints is partly the result of an increase in the use of “expedited” regulatory pathways that are aimed at speeding up the development, review, and approval of drugs.¹⁸ Over the past quarter century, lobbying by drug companies has put pressure on policy makers to establish several expedited pathways in Europe and the United States.¹⁹ These pathways also meet perceived patient demand for faster access to potentially effective therapies for conditions with substantial unmet needs.

In the US, the FDA “accelerated approval” pathway was established at the height of the HIV/AIDS crisis in the early 1990s. Other examples in the US include the “breakthrough therapy,” “priority review,” and “fast track” designations. Programmes in Europe include the European Medicines Agency’s “accelerated assessment” and “priority medicines” schemes.²⁰

The use of surrogate endpoints in expedited regulatory pathways may result in “conditional” approvals, in which drug manufacturers are legally mandated to conduct additional trials to prove the clinical benefit of their products. However, clinical efficacy of drugs initially approved on the basis of surrogate endpoints is often subsequently “confirmed” on the basis of other surrogate endpoints.^{21 22} For example, both pre-approval and mandated post-approval studies supporting FDA’s accelerated approval of crizotinib for metastatic non-small cell lung cancer used surrogate endpoints.²¹ This practice may meet regulators’ expectations but falls far short of reliable evidence of patient benefit.

Limited guidance from regulators and assessment bodies

There is little consensus for defining a “valid” surrogate, as it is difficult to set specific thresholds to grade the strength of association with the final clinical outcome. A few organisations, such as the German Institute for Quality and Efficiency in Healthcare (IQWiG), have prescriptive criteria for accepting surrogate endpoints. IQWiG sets a threshold for the lower bound of the confidence interval on the correlation coefficient ($R \geq 0.85$) to conclude a high correlation exists between the surrogate and final clinical outcome.²³ But most agencies have no similar cut-offs for accepting surrogate endpoints.

Methodological efforts for evaluating surrogate endpoints have a long history. In 2009, Taylor and Elston recommended a three step framework, based on biological plausibility alone, an observed association between the surrogate and the clinical endpoint at the individual patient level, and evidence from multiple randomised trials showing that drugs improving the effect on the surrogate also improve the final clinical outcome.²⁴ This framework was further extended to quantify the expected treatment effect on the final clinical outcome based on the surrogate.²⁵

However, regulatory agencies rarely use this framework. In 2018, the FDA published a table listing all surrogate endpoints that it has

used in its assessments without disclosing any information about their usefulness in predicting clinical benefit.²⁶ Academic researchers are increasingly filling this evidence gap and examining the strength of the association between surrogate endpoints that are commonly used by regulators and patient relevant clinical outcomes.^{27 28} In a recent study, researchers found only weak or missing correlations between surrogate endpoints and survival in breast cancer using the Taylor and Elston framework.²⁹ In another analysis, researchers found that none of the surrogate endpoints used in EMA expedited approvals had been independently evaluated.³⁰

Health technology assessment bodies also rarely use this framework to evaluate surrogate endpoints.³¹ Indeed, their guidance on the use of surrogate endpoints has been highly variable.³² In a recent survey of methodological guidance by 73 organisations, only 40% specifically considered surrogates.³³ Such variation yields heterogeneous conclusions about the relevance of the same putative surrogate endpoints across different settings.³⁴

Evaluating surrogate endpoints

Methodologists stress that evidence at the individual patient level is insufficient to evaluate surrogate endpoints, especially when such evidence is obtained from a single trial.³⁵ This is because the observed relationship between a surrogate and a clinical outcome for one drug may not hold for another, as it depends on the treatment’s mechanism of action.³⁵ For example, progression-free survival was previously shown to be a good surrogate for overall survival in advanced colorectal cancer based on evidence from trials of traditional chemotherapy.³⁶ However, the relationship is weaker between these endpoints for modern therapies with different mechanisms of action.³⁷

Meta-analysis, which combines data from several randomised trials, is more appropriate for evaluating the association between the treatment effects on the candidate surrogate endpoint and on the final patient relevant outcome.³⁸ Methodological consensus is growing for using bivariate meta-analysis methods to evaluate these relationships.^{39 44} These methods take into account not only the correlation between the treatment effects (quantifying the surrogate relationship), but also uncertainty around this relationship, which is crucial for decision making.^{44 45}

Table 1 gives some examples of candidate surrogate endpoints evaluated using meta-analysis methods with authors’ conclusions regarding the strength of the surrogate relationship. It is perhaps unsurprising that bevacizumab’s effect on progression-free survival never translated to prolonged survival for patients with metastatic breast cancer, as an earlier meta-analysis concluded that progression-free survival was not a good surrogate for overall survival in this setting.⁴⁹

Table 1 | Examples of candidate surrogate endpoints evaluated using meta-analysis and authors' conclusions regarding strength of surrogate relationship with the clinical outcome

Disease	Candidate surrogate endpoint	Clinical outcome	Strength of surrogate relationship
Gastric cancer ⁴	Disease-free survival	Overall survival	"Disease-free survival is an acceptable surrogate for overall survival in trials of cytotoxic agents for gastric cancer in the adjuvant setting"
Multiple sclerosis ⁴⁶	Relapse rate	Expanded Disability Status Scale (EDSS) worsening	"Findings support the use of commonly used surrogate markers of expanded disability status scale worsening as endpoints in multiple sclerosis clinical trials"
Immunoglobulin A nephropathy ⁴⁷	Change in proteinuria	Doubling of serum creatinine level, end-stage kidney disease, or death	"[Results support] the use of an early reduction in proteinuria as a surrogate endpoint for clinical endpoints in immunoglobulin A nephropathy in selected settings"
Cardiovascular disease ⁴⁸	Low-density lipoprotein	Major coronary events	"An approximately linear relationship between the absolute reductions in low-density lipoprotein cholesterol achieved in these trials and the proportional reductions in the incidence of coronary and other major vascular events"
Advanced colorectal cancer in traditional chemotherapy trials ³⁶	Progression-free survival	Overall survival	"PFS is an acceptable surrogate for OS in advanced colorectal cancer"
Advanced colorectal cancer in modern trials ³⁷	Progression-free survival	Overall survival	"None of the endpoints were found to achieve the level of evidence (i.e., mean $r^2_{\text{trial}} > 0.60$) that has been set to select high or excellent correlation levels by common surrogate evaluation tools"
Metastatic breast cancer ⁴⁹	Tumour response, disease control, progression-free survival, and time-to-progression	Overall survival	"No endpoint could be demonstrated as a good surrogate for overall survival in these trials"
Rectal cancer ⁵⁰	Pathological complete response and disease-free survival	Overall survival	"Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer"
Urinary cancer ⁵¹	Overall response rate and progression-free survival	Overall survival	"Overall response rate and progression-free survival are not reliable surrogate endpoints for median overall survival in trials of PD-(L)1 inhibitor therapy for urinary cancers"
Renal cell carcinoma ⁵²	Disease-free survival	Overall survival	"There was no strong correlation noted between 5-year disease-free survival and 5-year overall survival rates or between treatment effects on these endpoints"
Prostate cancer ⁵³	Event-free survival	Overall survival	"Event-free survival is a weak surrogate for overall survival and is not suitable for use as an intermediate clinical endpoint to substitute for overall survival"
HIV infection ⁵⁴	CD4 cell count	AIDS or death	"CD4 cell count is a weak surrogate endpoint"
Alzheimer's disease ¹	Amyloid levels	Cognitive decline	"Reducing amyloid levels with drug treatment has, at most, a small effect on cognition"

A potential problem when evaluating surrogate endpoints is the limited amount of randomised trial data in some areas—for example, for drugs targeting genetic biomarkers in small patient populations. In such cases, novel bivariate network meta-analysis methods,⁵⁵ or hierarchical models,⁵⁶ allow use of available data on similar drugs or drug classes.^{44 45}

Way forward

Regulators should be more selective in their use of surrogate endpoints. Surrogate endpoints should not be used when a drug's effect on the final clinical outcome can be observed within a relatively short time frame, as in acute conditions.⁵⁷ Hence, their use should be reserved for chronic diseases when they can provide early and accurate measurement of a drug's effect, especially when long follow-up is required before patient relevant clinical outcomes

can be assessed.⁵⁸ Even in such cases, regulators can use other tools to ensure patients who have exhausted all available treatment options can receive investigational treatments before regulatory approval.⁵⁹ Such "expanded access" programmes can bridge the access gap while evidence on patient relevant endpoints accrues.

When using surrogate endpoints is justified, regulators should consider the strength of available evidence on how well surrogates predict clinical benefit. The recent US accelerated approval of aducanumab for the treatment of Alzheimer's disease shows why this is essential. The FDA's decision was controversial partly because an earlier meta-analysis of randomised controlled trials showed that changes in amyloid level had little to no effect on cognition.¹ Thus, it is debatable whether a reduction in amyloid levels is an acceptable surrogate for cognition. This has also been reflected in

a report released by the Institute for Clinical and Economic Review, an independent health technology assessment body in the US.⁶⁰

In the absence of regulatory guidance, there are promising signs that assessment bodies are increasingly raising the bar for using surrogate endpoints. For example, NICE has recently proposed changes to strengthen the evidence requirements for the use of surrogate endpoints, while still allowing flexibility when desired evidence is not available.^{61 62} Involving assessment bodies in early regulatory interactions with manufacturers may help align evidence requirements on surrogate endpoints. The UK Innovative Licensing and Access Pathway managed by the Medicines and Healthcare Products Regulatory Agency, NICE, and the Scottish Medicines Consortium is aimed at facilitating such alignment.⁶³

Ultimately, regulatory and health technology assessment bodies need to weigh the strength of available evidence on the validity of surrogates alongside other considerations such as unmet therapeutic need. When making such trade-offs, quantifying how well a candidate surrogate predicts the final clinical outcome can provide valuable information.^{44 55} If recommended meta-analysis methods are used, the strength (or weakness) of the surrogate will be reflected in the uncertainty around the predicted treatment effect on the final outcome. A weaker surrogate will yield a larger interval and hence greater uncertainty.

Raising the bar for using surrogate endpoints may increase the cost and duration of drug development. However, this need not hamper pharmaceutical innovation. In the past, regulatory guidance encouraging manufacturers to evaluate the cardiovascular outcomes of diabetes treatments incentivised the generation of patient centred evidence without adversely affecting research and development.^{64 65}

Greater involvement of patients (and organisations representing patients) in regulatory and health technology assessment processes is also essential to ensure that the conditions for accepting surrogate endpoints for decision making are adequately met. When using such endpoints is justified, patients can help ensure that uncertainty related to surrogates is explicitly presented and taken into account. Patient input can also help guide decisions regarding the appropriate use of surrogate endpoints.

Key messages

- Surrogate endpoints are widely used by regulators to expedite the approval of new drugs, but most are not reliable predictors of outcomes that matter most to patients
- Regulators should only accept surrogate endpoints when generating data on clinical outcomes is not attainable
- When measuring clinical outcomes would require very long trials, the appropriateness of surrogate endpoints should be evaluated using meta-analysis

Contributors and sources: DD is an expert on health technology assessment methods research and has been involved in the ongoing update of NICE's health technology evaluation methods. HN's research examines the evidence supporting regulatory decisions on drugs in the US and Europe. OC has written extensively on the role of surrogate endpoints in healthcare policy and cost-effectiveness models. She previously contributed to the development of surrogate validation frameworks. SB has developed novel methods for modelling surrogate endpoints, which are proposed to be included in NICE's update of its methods guide. HN devised the idea for this article. All authors contributed to developing the first draft and writing of subsequent versions. DD is the guarantor.

Competing interests: DD is an employee of NICE, funded by grants from the European Union's IMI and Horizon 2020 research and innovation programme. SB has served as a paid consultant providing methodological advice to NICE, Roche and RTI Health Solutions. SB was supported by the Medical Research Council through the methodology research panel grants and has previously received research funding from European Federation of Pharmaceutical Industries & Associations (EFPIA) as part of unrelated European Union IMI GetReal project. HN previously received funding from the Pharmaceutical Group of the European Union for an unrelated systematic review on community pharmacists. HN currently receives funding from the Health Foundation on an unrelated project on pharmaceutical policy. OC received funding from the European Union's Horizon 2020 research and innovation programme.

The views expressed in this article are those of the authors and do not necessarily reflect those of their employers or funders.

Provenance and peer review: Not commissioned; externally peer reviewed.

- Ackley SF, Zimmerman SC, Brenowitz WD, et al. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. *BMJ* 2021;372:n156. doi: 10.1136/bmj.n156 pmid: 33632704
- Alexander GC, Emerson S, Kesselheim AS. Evaluation of aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility. *JAMA* 2021;325:1717-8. doi: 10.1001/jama.2021.3854 pmid: 33783469
- Chen EY, Joshi SK, Tran A, Prasad V. Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials. *JAMA Intern Med* 2019;179:642-7. doi: 10.1001/jamainternmed.2018.8351 pmid: 30933235
- Oba K, Paoletti X, Alberts S, et al GASTRIC group. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. *J Natl Cancer Inst* 2013;105:1600-7. doi: 10.1093/jnci/djt270 pmid: 24108812
- Yudkin JS, Lipska KJ, Montori VM. The idolatry of the surrogate. *BMJ* 2011;343:d7995. doi: 10.1136/bmj.d7995 pmid: 22205706
- Raphael MJ, Robinson A, Booth CM, et al. The value of progression-free survival as a treatment end point among patients with advanced cancer: a systematic review and qualitative assessment of the literature. *JAMA Oncol* 2019;5:1779-89. doi: 10.1001/jamaoncol.2019.3338 pmid: 31556921
- Prasad V, Kim C, Burotto M, Vandross A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. *JAMA Intern Med* 2015;175:1389-98. doi: 10.1001/jamainternmed.2015.2829 pmid: 26098871
- Hwang TJ, Gyawali B. Association between progression-free survival and patients' quality of life in cancer clinical trials. *Int J Cancer* 2019;144:1746-51. doi: 10.1002/ijc.31957 pmid: 30374970
- Kovic B, Jin X, Kennedy SA, et al. Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis. *JAMA Intern Med* 2018;178:1586-96. doi: 10.1001/jamainternmed.2018.4710 pmid: 30285081
- Svensson S, Menkes DB, Lexchin J. Surrogate outcomes in clinical trials: a cautionary tale. *JAMA Intern Med* 2013;173:611-2. doi: 10.1001/jamainternmed.2013.3037 pmid: 23529157
- Carpenter D, Kesselheim AS, Joffe S. Reputation and precedent in the bevacizumab decision. *N Engl J Med* 2011;365:e3. doi: 10.1056/NEJMp1107201 pmid: 21707383
- Tap WD, Wagner AJ, Schöffski P, et al ANNOUNCE Investigators. Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the announce randomized controlled trial. *JAMA* 2020;323:1266-76. doi: 10.1001/jama.2020.1707 pmid: 32259228
- Chang CY, Nguyen CP, Wesley B, Guo J, Johnson LL, Joffe HV. Withdrawal approval of Makena—the FDA Center for Drug Evaluation and Research. *N Engl J Med* 2020;383:e131. doi: 10.1056/NEJMp2031055 pmid: 33140923
- Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. *Lancet* 2018;391:748-57. doi: 10.1016/S0140-6736(17)33297-X pmid: 29268948
- Kumar S, Rajkumar SV. Surrogate endpoints in randomised controlled trials: a reality check. *Lancet* 2019;394:281-3. doi: 10.1016/S0140-6736(19)31711-8 pmid: 31354129
- Zhang AD, Puthumana J, Downing NS, Shah ND, Krumholz HM, Ross JS. Assessment of clinical trials supporting US Food and Drug Administration approval of novel therapeutic agents, 1995-2017. *JAMA Netw Open* 2020;3:e203284. doi: 10.1001/jamanetworkopen.2020.3284 pmid: 32315070
- Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. *JAMA* 2014;311:368-77. doi: 10.1001/jama.2013.282034 pmid: 24449315
- Wallach JD, Ross JS, Naci H. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements. *Clin Trials* 2018;15:219-29. doi: 10.1177/1740774518770648 pmid: 29871509
- Darrow JJ, Avorn J, Kesselheim AS. FDA approval and regulation of pharmaceuticals, 1983-2018. *JAMA* 2020;323:164-76. doi: 10.1001/jama.2019.20288 pmid: 31935033
- Neez E, Hwang TJ, Sahoo SA, Naci H. European Medicines Agency's priority medicines scheme at 2 years: an evaluation of clinical studies supporting eligible drugs. *Clin Pharmacol Ther* 2020;107:541-52. doi: 10.1002/cpt.1669 pmid: 31591708
- Naci H, Smalley KR, Kesselheim AS. Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration. *JAMA* 2017;318:626-36. doi: 10.1001/jama.2017.9415 pmid: 28810023
- Gyawali B, Hey SP, Kesselheim AS. Assessment of the clinical benefit of cancer drugs receiving accelerated approval. *JAMA Intern Med* 2019;179:906-13. doi: 10.1001/jamainternmed.2019.0462 pmid: 31135808
- Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Aussagekraft von Surrogatendpunkten in der onkologie. [Validity of surrogate parameters in oncology (Rapid report)]. Cologne, 2011.
- Taylor RS, Elston J. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK health technology assessment reports. *Health Technol Assess* 2009;13:iii, ix-xi, 1-50. doi: 10.3310/hta13080 pmid: 19203465

- 25 Ciani O, Buyse M, Drummond M, Rasi G, Saad ED, Taylor RS. Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework. *Nat Rev Drug Discov* 2016;15:516-516. doi: 10.1038/nrd.2016.81 pmid: 27256477
- 26 US Food & Drug Administration. Table of surrogate endpoints that were the basis of drug approval or licensure. 2021. <https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure>
- 27 Kim C, Prasad V. Strength of validation for surrogate end points used in the US Food and Drug Administration's approval of oncology drugs. *Mayo Clin Proc* 2016;10:S0025-6196(16)00125-7. doi: 10.1016/j.mayocp.2016.02.012 pmid: 27236424
- 28 Haslam A, Hey SP, Gill J, Prasad V. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. *Eur J Cancer* 2019;106:196-211. doi: 10.1016/j.ejca.2018.11.012 pmid: 30528804
- 29 Gyawali B, Hey SP, Kesselheim AS. Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs. *EClinicalMedicine* 2020;21:100332. doi: 10.1016/j.eclinm.2020.100332 pmid: 32382717
- 30 Schuster Bruce C, Brhlkova P, Heath J, McGettigan P. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018. *PLoS Med* 2019;16:e1002873. doi: 10.1371/journal.pmed.1002873 pmid: 31504034
- 31 Ciani O, Grigore B, Blommestein H, et al. Validity of surrogate endpoints and their impact on coverage recommendations. A retrospective analysis across international health technology assessment agencies. *Med Decis Making* 2021;41:439-52. doi: 10.1177/0272989X21994553 pmid: 33719711
- 32 Velasco Garrido M, Mangiapane S. Surrogate outcomes in health technology assessment: an international comparison. *Int J Technol Assess Health Care* 2009;25:315-22. doi: 10.1017/S0266462309990213 pmid: 19619350
- 33 Grigore B, Ciani O, Dams F, et al. Surrogate endpoints in health technology assessment: an international review of methodological guidelines. *Pharmacoeconomics* 2020;38:1055-70. doi: 10.1007/s40273-020-00935-1 pmid: 32572825
- 34 Ciani O, Davis S, Tappenden P, et al. Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers. *Int J Technol Assess Health Care* 2014;30:312-24. doi: 10.1017/S0266462314000300 pmid: 25308694
- 35 Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? *Ann Intern Med* 1996;125:605-13. doi: 10.7326/0003-4819-125-7-199610010-00011 pmid: 8815760
- 36 Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. *J Clin Oncol* 2007;25:5218-24. doi: 10.1200/JCO.2007.11.8836 pmid: 18024867
- 37 Ciani O, Buyse M, Garside R, et al. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. *J Clin Epidemiol* 2015;68:833-42. doi: 10.1016/j.jclinepi.2015.02.016 pmid: 25863582
- 38 Joffe MM, Greene T. Related causal frameworks for surrogate outcomes. *Biometrics* 2009;65:530-8. doi: 10.1111/j.1541-0420.2008.01106.x pmid: 18759836
- 39 Bujkiewicz S, Thompson JR, Spata E, Abrams KR. Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints. *Stat Methods Med Res* 2017;26:2287-318. doi: 10.1177/0962280215597260 pmid: 26271918
- 40 Bujkiewicz S, Thompson JR, Riley RD, Abrams KR. Bayesian meta-analytical methods to incorporate multiple surrogate endpoints in drug development process. *Stat Med* 2016;35:1063-89. doi: 10.1002/sim.6776 pmid: 26530518
- 41 Burzykowski T, Molenberghs G, Buyse M, et al. Validation of surrogate end points in multiple randomized clinical trials with failure time end points. *J R Stat Soc Ser C Appl Stat* 2001;50:405-22. doi: 10.1111/1467-9876.00244
- 42 Daniels MJ, Hughes MD. Meta-analysis for the evaluation of potential surrogate markers. *Stat Med* 1997;16:1965-82. doi: 10.1002/(SICI)1097-0258(19970915)16:17<1965::AID-SIM630>3.0.CO;2-M pmid: 9304767
- 43 Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. *Biostatistics* 2000;1:49-67. doi: 10.1093/biostatistics/1.1.49 pmid: 12933525
- 44 Bujkiewicz S, Achana F, Papanikos T, et al. NICE DSU technical support document 20: Multivariate meta-analysis of summary data for combining treatment effects on correlated outcomes and evaluating surrogate endpoints. 2019. <http://nicedsu.org.uk/wp-content/uploads/2020/10/TSD-20-mvmeta-final.pdf>
- 45 Welton N, Phillippo D, Owen R, et al. CHTE2020 sources and synthesis of evidence: update to evidence synthesis methods report by the decision support unit. 2020. http://nicedsu.org.uk/wp-content/uploads/2020/11/CHTE-2020_final_20April2020_final.pdf
- 46 Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P. Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. *Neurology* 2010;75:302-9. doi: 10.1212/WNL.0b013e3181ea15aa. pmid: 20574036
- 47 Inker LA, Mondal H, Greene T, et al. Early change in urine protein as a surrogate end point in studies of iga nephropathy: an individual-patient meta-analysis. *Am J Kidney Dis* 2016;68:392-401. doi: 10.1053/j.ajkd.2016.02.042 pmid: 16214597
- 48 Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005;366:1267-78. doi: 10.1016/S0140-6736(05)67394-1 pmid: 16214597
- 49 Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. *J Clin Oncol* 2008;26:1987-92. doi: 10.1200/JCO.2007.10.8407 pmid: 18421050
- 50 Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials. *J Gastrointest Oncol* 2017;8:39-48. doi: 10.21037/jgo.2016.11.03 pmid: 28280607
- 51 Abdel-Rahman O. Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review. *Immunotherapy* 2018;10:139-48. doi: 10.2217/imt-2017-0115 pmid: 29260622
- 52 Harshman LC, Xie W, Moreira RB, et al. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: a trial-level meta-analysis. *Cancer* 2018;124:925-33. doi: 10.1002/cncr.31154 pmid: 29266178
- 53 Xie W, Regan MM, Buyse M, et al. CEaP Working Group. Event-free survival, a prostate-specific antigen-based composite end point, is not a surrogate for overall survival in men with localized prostate cancer treated with radiation. *J Clin Oncol* 2020;38:3032-41. doi: 10.1200/JCO.19.03114 pmid: 32552276
- 54 Hughes MD, Daniels MJ, Fischl MA, Kim S, Schooley RT. CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group. *AIDS* 1998;12:1823-32. doi: 10.1097/00002030-199814000-00014 pmid: 9792383
- 55 Bujkiewicz S, Jackson D, Thompson JR, et al. Bivariate network meta-analysis for surrogate endpoint evaluation. *Stat Med* 2019;38:3322-41. doi: 10.1002/sim.8187 pmid: 31131475
- 56 Papanikos T, Thompson JR, Abrams KR, et al. Bayesian hierarchical meta-analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data. *Stat Med* 2020;39:1103-24. doi: 10.1002/sim.8465 pmid: 31990083
- 57 Institute of Medicine (US) Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease. *Evaluation of biomarkers and surrogate endpoints in chronic disease*. 2010. <https://www.ncbi.nlm.nih.gov/books/NBK220297/>
- 58 Burzykowski T, Molenberghs G, Buyse M. *The evaluation of surrogate endpoints*. 2010. <https://link.springer.com/book/10.1007/b138566#about>
- 59 Darrow JJ, Sarpatwari A, Avorn J, Kesselheim AS. Practical, legal, and ethical issues in expanded access to investigational drugs. *N Engl J Med* 2015;372:279-86. doi: 10.1056/NEJMe1409465 pmid: 25587952
- 60 Institute for Clinical and Economic Review (ICER). "Aducanumab for Alzheimer's Disease: Final Policy Recommendations". August 2021. Available at: [ICER_ALZ_Policy_Recommendations_080521.pdf](https://icer.org/ALZ_Policy_Recommendations_080521.pdf)
- 61 National Institute for Health and Care Excellence. CHTE methods review: sources and synthesis of evidence Task and finish group report. 2020. <https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/chte-methods-consultation>
- 62 National Institute for Health and Care Excellence. The NICE methods of health technology evaluation: the case for change. 2020. <https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/chte-methods-consultation>
- 63 Medicines and Healthcare Products Regulatory Agency. Innovative licensing and access pathway. 2021. <https://www.gov.uk/guidance/innovative-licensing-and-access-pathway>
- 64 Sharma A, Pagidipati NJ, Califf RM, et al. Impact of regulatory guidance on evaluating cardiovascular risk of new glucose-lowering therapies to treat type 2 diabetes mellitus: lessons learned and future directions. *Circulation* 2020;141:843-62. doi: 10.1161/CIRCULATIONAHA.119.041022 pmid: 31992065
- 65 Hwang TJ, Franklin JM, Kesselheim AS. Effect of US Food and Drug Administration's cardiovascular safety guidance on diabetes drug development. *Clin Pharmacol Ther* 2017;102:290-6. doi: 10.1002/cpt.705 pmid: 28390139